Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMYD3 | Q9H7B4 | 6/20 | 0.54 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.53 |
| ▸ | SIGMAR1 | Q99720 | 5/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | CCR2 | P41597 | 1/20 | 0.46 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11627073 | 0.94 | EPHX2 (0.58) | SMYD3EPHX2SIGMAR1LMNAKMT2A | |
| SCHEMBL11626245 | 0.89 | EPHX2 (0.57) | SMYD3EPHX2SIGMAR1LMNAKMT2A | |
| SCHEMBL11629386 | 0.88 | EPHX2 (0.68) | SMYD3EPHX2SIGMAR1LMNAKMT2A | |
| SCHEMBL11627838 | 0.87 | EPHX2 (0.52) | SMYD3EPHX2SIGMAR1LMNAKMT2A | |
| SCHEMBL11629518 | 0.87 | EPHX2 (0.70) | SMYD3EPHX2SIGMAR1LMNAKMT2A | |
| SCHEMBL30590228 | 0.83 | EPHX2 (0.71) | SMYD3EPHX2SIGMAR1LMNAKMT2A | |
| SCHEMBL19701393 | 0.81 | SMYD3 (0.80) | SMYD3EPHX2SIGMAR1KMT2ACCR2 | |
| SCHEMBL21489802 | 0.81 | SMYD3 (0.80) | SMYD3EPHX2SIGMAR1KMT2ACCR2 | |
| SCHEMBL15271856 | 0.81 | EPHX2 (0.48) | SMYD3EPHX2SIGMAR1MAP4K4 | |
| SCHEMBL15271984 | 0.81 | SMYD3 (0.51) | SMYD3EPHX2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10695346-B2 | 4,6-pyrimidinylene derivatives and uses thereof | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-06-30 | — | — | US | disclosed |
| US-20180110778-A1 | 4,6-PYRIMIDINYLENE DERIVATIVES AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2018-04-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10695346-B2 | 4,6-pyrimidinylene derivatives and uses thereof | CDK3, CDK1, CDK14 | SMYD3 2424/4885EPHX2 1366/4885SIGMAR1 4353/4885 |
| US-20180110778-A1 | 4,6-PYRIMIDINYLENE DERIVATIVES AND USES THEREOF | CDKL4, CDKL5, PIP5K1A | SMYD3 2995/4885EPHX2 1948/4885SIGMAR1 4011/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.